Pharmacyclics' Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types...(s well as angiogenesis or the growth of ...),Health

Date:4/16/2008

s well as angiogenesis, or the growth of new blood vessels that supply the tumors with nutrients and oxygen. Activation of Factor VII (Factor VIIa) by tissue factor also leads to the high incidence of thrombotic complications seen in cancer patients. PCI-27483 selectively inhibits Factor VIIa when it is complexed with tissue factor.

"We're encouraged by the promising preclinical results with PCI-27483 as we broaden our portfolio of product opportunities," said Richard A. Miller, M.D., president and chief executive officer of Pharmacyclics. "We are working to move additional drug candidates forward from our diverse pipeline, including an HDAC inhibitor, now in a Phase 1 clinical trial for solid tumors, and motexafin gadolinium, which is currently in two Phase 2 trials sponsored by the National Cancer Institute."

About Pharmacyclics

Pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and other serious diseases. The company is leveraging its small-molecule drug development expertise to build a pipeline in oncology and other diseases based on a wide range of targets, pathways and mechanisms. More information about the company, its technology, and products can be found at http://www.pharmacyclics.com. Pharmacyclics(R) and the "pentadentate" logo(R) are registered trademarks of Pharmacyclics, Inc.

NOTE: Other than statements of historical fact, the statements made in this press release about plans for filing an IND for PCI-27483, and other future plans for our clinical trials, progress of and reports of results from preclinical and clinical studies, clinical development plans and product development and corporate partnering activities are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. The words "project," "believe," "will," "may," "continue," "plan," "expect," "intend," "anticipate," variations of such w
'/>"/>

SOURCE Pharmacyclics, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
2. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
3. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
4. Genmab A/S - Company Announcement: Novel Insights into HuMax-EGFr Mechanisms of Action Published in PNAS
5. FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment
6. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
7. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
8. Parion Sciences Announces Phase I Clinical Results for Novel Dry Mouth Treatment
9. NeoVista Presents One Year Data on Novel Wet AMD Therapy at Macula Society
10. Sangart Completes Enrollment in Phase III Study of Its Novel Blood Substitute Hemospan
11. Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health